Platinum Priority – Collaborative Review – Kidney CancerEditorial by Noel W. Clarke on pp. 829–830 of this issueIntegrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials
Introduction
Renal cell carcinoma (RCC) is the most common type of renal cancer, accounting for approximately 3% of all adult malignancies and 90–95% of all kidney neoplasms [1], [2]. In the European Union (25 countries), there were over 60 000 new cases of kidney cancer and 26 000 deaths in 2006 alone [3]. Worldwide, mortality as a result of RCC currently exceeds 100 000 patients each year [4], with the incidence and mortality rate increasing by 2–3% per decade [1].
Metastatic disease is present in >25% of patients at diagnosis of RCC, and almost 95% of these have multiple sites affected [1]. The disease remains one of the most treatment-resistant malignancies and is associated with a poor prognosis [5]. Reports maintain that only approximately 23% of patients presenting with metastatic RCC (mRCC) will be alive 5 yr later [6].
Surgical intervention is the primary treatment for early-stage RCC; however, surgery alone has limited benefit in patients with metastatic disease, except for palliative reasons [1]. For advanced or metastatic disease, nephrectomy may only be curative if all metastatic deposits are excised [7]. Therefore, a combination of surgery and targeted therapy is increasingly being used for locally advanced and mRCC in an attempt to improve patient outcomes. Prior to the advent of antiangiogenic agents, systemic treatment options for mRCC were limited to cytokine therapies (ie, interleukin [IL]-2 and interferon-alpha [IFN-α]). In the past few years, a shift in the treatment paradigm for RCC has occurred with the introduction of receptor tyrosine kinase inhibitors (TKIs), vascular endothelial growth factor (VEGF) antibodies, and mammalian target of rapamycin inhibitors (mTORs). Several antiVEGF therapies have been approved for use in advanced RCC in the past 5 yr. These include sorafenib, sunitinib, and pazopanib; small molecule inhibitors of VEGF receptors (VEGFRs); platelet-derived growth factor receptors (PDGFRs); c-Kit; and Flt-3 [8], [9], [10]. In addition, bevacizumab, an antiVEGF antibody, was approved in combination with IFN-α [11], [12]. Efficacy and toxicities have been extensively reported. Of note, most patients studied with these agents had clear-cell RCC, good or intermediate performance status (PS), and had undergone prior nephrectomy (85–94%).
The mTOR inhibitor temsirolimus has been approved in patients with mRCC who present with at least three of six poor prognostic risk factors, and everolimus for patients with mRCC who have failed prior antiVEGF therapy [13]. The pivotal study for temsirolimus revealed a greater benefit for temsirolimus relative to IFN-α in patients who had not undergone a prior nephrectomy, but the results do not tell us about the outcomes in the nephrectomy versus non-nephrectomy groups [14]. At this time, there are no data available to definitively guide us on the optimal integration of temsirolimus with cytoreductive nephrectomy (CN).
Collectively, these agents show superior efficacy over IL-2 and IFN-α, and have allowed for a substantial improvement in the disease treatment. This article will give an overview of approved and emerging targeted therapies for RCC and describe how they may be integrated with surgery in management of the disease.
Section snippets
Evidence acquisition
A nonsystematic review was performed based on a literature search of MEDLINE for reports on surgery, receptor TKIs, VEGF antibodies, mTORs, and cytokine adjuvant therapy relating to RCC. In addition, registries of clinical trials (eg, www.clinicaltrials.gov) were searched. Abstracts of meeting proceedings were included in the review and analysis, provided they were retrievable from the public domain, to ensure an up-to-date review of a rapidly evolving field.
Evidence synthesis
With the retrieved literature, abstracts, and clinical trial information, an evidence synthesis was performed for: 1) the combination of VEGF-targeted therapies with surgery in mRCC; 2) adjuvant use of VEGF-targeted therapy in nonmetastatic high-risk patients; 3) neoadjuvant and presurgical treatment of unresectable RCC; 4) safety of VEGF-targeted therapy in combination with surgery; and 5) new agents for the treatment of RCC that may be integrated with surgery.
Conclusions
The recent interest surrounding the multimodal approach of integrating drug therapies with surgery for the treatment of RCC is a direct response to the advent of targeted therapies with specific molecular mechanisms of action. The encouraging response data in both primary tumors and metastases suggest that this is a rational step in the evolution of RCC treatment.
Presently, we do not have definitive evidence supporting changes in the current treatment paradigms. In the absence of prospective
References (78)
- et al.
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
Cancer Treat Rev
(2008) - et al.
Estimates of the cancer incidence and mortality in Europe in 2006
Ann Oncol
(2007) - et al.
Renal cell carcinoma guideline
Eur Urol
(2007) - et al.
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Lancet
(2007) - et al.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Lancet
(2008) - et al.
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
Lancet
(2001) - et al.
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis
J Urol
(2004) - et al.
Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma
Am J Pathol
(2001) - et al.
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma
J Urol
(2009) - et al.
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis
Eur Urol
(2009)